Johnson & Johnson vaccine shows 66% efficacy overall

Meg Tirrell reports the Johnson & Johnson vaccine has shown 66 percent efficacy overall and that the U.S. has already ordered 100 million doses. The J&J Covid-19 vaccine is likely to approved by early February. Moderna is also seeking permission to increase doses per vial to address the supply chain problem.